DBV Technologies Reports H1-20
DBV Technologies Reports H1-20
themarketsignal.com/Free-Report/DBVT
DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20. This compares with €172.0 million in the previous half year ending December 31, 2019, reflecting €53.8 million increase.
The company used €79.4 million cash in operating activities, while €1.3 million was generated from investment activities. DBVT reported €7.6 million operating income in H1-20 as against €7.1 million in H1-19. This income generation is attributed to income recognized from Research Tax Credit of the Company.
During the first half of this year, the company reported €86.5 million net loss, as against €79.8 million in H1-19.
themarketsignal.com/Free-Report/DBVT
DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20. This compares with €172.0 million in the previous half year ending December 31, 2019, reflecting €53.8 million increase.
The company used €79.4 million cash in operating activities, while €1.3 million was generated from investment activities. DBVT reported €7.6 million operating income in H1-20 as against €7.1 million in H1-19. This income generation is attributed to income recognized from Research Tax Credit of the Company.
During the first half of this year, the company reported €86.5 million net loss, as against €79.8 million in H1-19.
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.